JP2007230983A - Prostatic hypertrophy inhibitor - Google Patents
Prostatic hypertrophy inhibitor Download PDFInfo
- Publication number
- JP2007230983A JP2007230983A JP2006084136A JP2006084136A JP2007230983A JP 2007230983 A JP2007230983 A JP 2007230983A JP 2006084136 A JP2006084136 A JP 2006084136A JP 2006084136 A JP2006084136 A JP 2006084136A JP 2007230983 A JP2007230983 A JP 2007230983A
- Authority
- JP
- Japan
- Prior art keywords
- prostatic hypertrophy
- extract
- contained
- dokudami
- houttuynia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
前立腺肥大抑制を目的とした医薬品、飲食品または動物用飼料に関する。The present invention relates to pharmaceuticals, foods and drinks or animal feeds for the purpose of suppressing prostate hypertrophy.
前立腺は男性ホルモン依存的に肥大することが知られている。40歳を過ぎたころから前立腺が肥大し始め、高齢者の半数以上の男性が夜間頻尿、放尿力の低下などの障害を訴えるようになり、男性にとっては深刻な問題となっている。現在、前立腺肥大の予防改善食品としてノコギリヤシエキス、カボチャ種子エキスなど、医薬品としてはα1−ブロッカー、抗アンドロゲン剤などが用いられているが、選択肢が少ないため新たな前立腺肥大を抑制する飲食品や医薬品の開発が望まれている。It is known that the prostate enlarges in an androgen-dependent manner. Since the age of 40 years old, the prostate began to enlarge, and more than half of the elderly men complained of problems such as nocturia and decreased urination, which is a serious problem for men. Currently, α1-blockers, antiandrogens, etc. are used as pharmaceuticals such as saw palmetto extract and pumpkin seed extract as foods for preventing and improving prostate hypertrophy. Development is desired.
ドクダミは独特の臭気を有する植物で、洗って日干しにしたものを十薬(じゅうやく)という。高血圧、動脈硬化の予防、急性腎炎、あせも、湿疹などに効果があると言われてり、お茶などにして売られている。しかしドクダミが前立腺肥大の予防、治療に有効であるという報告は全くない。Dokudami is a plant with a unique odor, and what is washed and sun-dried is called ten medicines. It is said to be effective for high blood pressure, prevention of arteriosclerosis, acute nephritis, and hot eczema, and is sold as tea. However, there is no report that Dokudami is effective in preventing and treating prostate enlargement.
前立腺肥大抑制を目的とした医薬品、飲食品または動物用飼料を提供することにある。It is to provide pharmaceuticals, foods and drinks or animal feeds for the purpose of suppressing prostate hypertrophy.
上記の課題を解決するために鋭意検討を重ねた結果、ドクダミに顕著な前立腺肥大抑制作用があることを見出した。すなわち、本発明は、ドクダミを有効成分とする前立腺肥大抑制を目的とした医薬品、飲食品または動物用飼料を提供する。As a result of intensive studies in order to solve the above-mentioned problems, it was found that Dokudami has a remarkable effect of suppressing prostate hypertrophy. That is, the present invention provides pharmaceuticals, foods and drinks, or animal feeds for the purpose of suppressing prostatic hypertrophy with dokudami as an active ingredient.
本発明により、ドクダミを有効成分とする前立腺肥大抑制を目的とした医薬品、飲食品または動物用飼料を提供することができる。ADVANTAGE OF THE INVENTION By this invention, the pharmaceutical, food-drinks, or animal feed aiming at the suppression of the prostatic hypertrophy which uses dokudami as an active ingredient can be provided.
本発明に関わるドクダミは、Houttuynia cordata Thunbをさす。The dokudami related to the present invention refers to Houttynia cordadata chumb.
本発明に関わるドクダミは、植物全体、又は葉部をそのまま用いても良く、これらを乾燥した乾燥体、もしくは乾燥後粉砕し粉末を用いることもできる。また、これらを水、またはアルコールなどの有機溶媒などで抽出したものを用いることもできる。The whole body or a leaf part may be used as it is for the damselfly related to the present invention, and a dried product obtained by drying these, or a powder obtained by pulverizing after drying can also be used. Moreover, what extracted these with water or organic solvents, such as alcohol, can also be used.
本発明に関わる前立腺肥大抑制剤を製造するには、上記の方法で製造したドクダミまたはその抽出物を用い、常法に従って公知の無毒性担体と組み合わせて製剤化すればよい。本発明に関わる前立腺肥大抑制剤は、種々の剤型での投与が可能であり、例えば、経口投与剤としては錠剤、顆粒剤、散剤、カプセル剤、ソフトカプセル剤等の固形剤、溶液剤、懸濁剤、乳剤等の液剤等が挙げられ、非経口投与剤としては、注射剤のほか、坐剤、嘖霧剤、経皮吸収剤等が挙げられ、これらの製剤は製剤上の常套手段により調整することができる。上記の無毒性担体としては、例えば、グルコース、乳糖、ショ糖、澱粉、マンニトール、デキストリン、脂肪酸グリセリド、ポリエチレングリコール、ヒドロキシエチルデンプン、エチレングリコール、ポリオキシエチレンソルビタン脂肪酸エステル、アミノ酸、アルブミン、水、生理食塩水等が挙げられる。また、必要に応じて、安定化剤、滑剤、湿潤剤、乳化剤、結合剤等の慣用の添加剤を適宜添加することができる。本発明に関わる前立腺肥大抑制剤において、ドクダミの投与量は、患者の年齢、体重、症状、疾患の程度、投与スケジュール、製剤形態などにより、適宜選択・決定されるが、例えば、一日あたり0.001−1g/kg体重程度とされ、一日数回に分けて投与してもよい。In order to produce the prostatic hypertrophy inhibitor according to the present invention, the dokudami produced by the above method or an extract thereof may be used in combination with a known non-toxic carrier according to a conventional method. The prostatic hypertrophy inhibitor according to the present invention can be administered in various dosage forms. For example, oral administration agents include solid agents such as tablets, granules, powders, capsules, and soft capsules, solutions, and suspensions. Examples of the parenteral preparation include injections, suppositories, sprays, and percutaneous absorption agents. These preparations are prepared by conventional means in the preparation. Can be adjusted. Examples of the non-toxic carrier include glucose, lactose, sucrose, starch, mannitol, dextrin, fatty acid glyceride, polyethylene glycol, hydroxyethyl starch, ethylene glycol, polyoxyethylene sorbitan fatty acid ester, amino acid, albumin, water, physiological Examples include saline. If necessary, conventional additives such as stabilizers, lubricants, wetting agents, emulsifiers, binders and the like can be appropriately added. In the prostatic hypertrophy inhibitor according to the present invention, the dose of dokudami is appropriately selected and determined according to the patient's age, weight, symptom, degree of disease, administration schedule, formulation form, etc. The dose is about 0.01-1 g / kg body weight, and may be administered in several divided doses a day.
また、本発明に関わるドクダミは、食経験も豊富なことから安全性が高く、前立腺肥大抑制を目的として、飲食品として摂取することもできる。本発明に関わるドクダミを含有することを特徴とする飲食品は、特定保健用食品、栄養機能性食品、又は健康食品として位置づけることができる。飲食品としては、上記の方法で製造したドクダミまたは抽出物をそのまま用いる他、例えば、適当な助剤を添加した後、慣用の手段を用いて、食用に適した形態、例えば、顆粒状、粒状、錠剤、カプセル剤、ペースト状等に形成したものを用いることができる。この飲食品は、そのまま食用に供してもよく、また種々の飲食品(例えばハム、ソーセージ、かまぼこ、ちくわ、パン、バター、粉乳、菓子など)に添加して使用したり、水、酒類、果汁、牛乳、清涼飲料水等の飲物に添加して使用してもよい。かかる飲食品の形態における本発明の摂取量は、年齢、体重、症状、摂取スケジュール、製剤形態などにより、適宜選択・決定されるが、例えば、一日あたり0.001−1g/kg体重程度とされる。In addition, the dokudami related to the present invention is highly safe because it has abundant eating experience, and can be taken as a food or drink for the purpose of suppressing prostate hypertrophy. The food / beverage products characterized by containing the dokudami concerning this invention can be positioned as a food for specific health, a nutritional functional food, or a health food. As food and drink, in addition to using the dokudami or extract produced by the above method as it is, for example, after adding a suitable auxiliary agent, using conventional means, a form suitable for food, for example, granular, granular , Tablets, capsules, pastes and the like can be used. This food and drink may be used for food as it is, and used by adding it to various foods and drinks (for example, ham, sausage, kamaboko, chikuwa, bread, butter, milk powder, confectionery, etc.), water, alcoholic beverages, fruit juice It may be used by adding to drinks such as milk and soft drinks. The amount of intake of the present invention in the form of such food and drink is appropriately selected and determined according to age, weight, symptoms, intake schedule, formulation form, etc., for example, about 0.001-1 g / kg body weight per day Is done.
以下に本発明をより詳細に説明するために実施例を挙げるが、本発明はこれらによって何ら限定されるものではない。Examples are given below to describe the present invention in more detail, but the present invention is not limited by these.
実施例1 ドクダミの前立腺肥大抑制作用
ドクダミによる前立腺肥大抑制効果を調べるために以下の実験を行った。ドクダミの葉粗切物(100g)を10倍量のメタノールに一日浸漬し、抽出液を減圧乾固し、得られた抽出物を被験試料とした。7週齢雄ddYマウスの精巣を摘出した。精巣摘出マウスを3群(n=8)に分け、A群にはコーンオイルをB、C群にはコーンオイルに溶解したテストステロン(52mg/kg)を2週間腹腔内投与した。また、A、B群には水を、C群にはドクダミメタノール抽出物の水溶液(100mg/kg)を2週間経口投与した。2週間後に解剖し、前立腺、精嚢腺の大きさを測定した。精巣摘出したマウスの前立腺は非常に小さいため正確な重量測定が困難であったため、摘出せず開腹状態のまま、実体顕微鏡下で精密ノギスを用いて長径および短径の長さを測定した。精嚢腺は摘出して重量測定を行った。その結果を表1に示す。測定値は平均値±標準誤差を示す。*はA群に対してp<0.05であるものに付した(Studentのt−test)。Example 1 Prostatic hypertrophy inhibitory effect of dokudami The following experiment was conducted to examine the prostatic hypertrophy inhibitory effect of dokudami. A rough cut leaf (100 g) of Dokudami was immersed in 10 times the amount of methanol for one day, the extract was dried under reduced pressure, and the resulting extract was used as a test sample. The testis of 7-week old male ddY mice was removed. Testis-extracted mice were divided into 3 groups (n = 8), corn oil B was administered to group A, and testosterone (52 mg / kg) dissolved in corn oil was intraperitoneally administered to group C for 2 weeks. In addition, water was administered to the A and B groups, and an aqueous solution (100 mg / kg) of a docamimethanol extract was orally administered to the C group for 2 weeks. Two weeks later, the animals were dissected and the sizes of the prostate and seminal vesicles were measured. Since the prostate of the testis-extracted mouse was very small and accurate weight measurement was difficult, the length of the major axis and the minor axis were measured using a precision caliper under a stereomicroscope without removing the prostate. The seminal vesicles were removed and weighed. The results are shown in Table 1. The measured value indicates an average value ± standard error. * Is attached to the case where p <0.05 with respect to Group A (Student's t-test).
この結果より、ドクダミ抽出物はテストステロンによる前立腺の肥大を顕著に抑制することが示された。従って、ドクダミは前立腺肥大の予防・改善に有用である。From this result, it was shown that the extract of Dokudami remarkably suppresses the enlargement of the prostate due to testosterone. Therefore, Dokudami is useful for preventing and improving prostate enlargement.
本発明により、ドクダミを有効成分とする前立腺肥大抑制を目的とした医薬品または飲食品を提供することができる。ADVANTAGE OF THE INVENTION By this invention, the pharmaceutical or food-drinks aiming at the suppression of the prostatic hypertrophy which uses dokudami as an active ingredient can be provided.
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006084136A JP2007230983A (en) | 2006-02-27 | 2006-02-27 | Prostatic hypertrophy inhibitor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006084136A JP2007230983A (en) | 2006-02-27 | 2006-02-27 | Prostatic hypertrophy inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2007230983A true JP2007230983A (en) | 2007-09-13 |
Family
ID=38551931
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006084136A Pending JP2007230983A (en) | 2006-02-27 | 2006-02-27 | Prostatic hypertrophy inhibitor |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2007230983A (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010088367A (en) * | 2008-10-09 | 2010-04-22 | S Net:Kk | Livestock feed |
CN101856418A (en) * | 2010-04-27 | 2010-10-13 | 贵阳春科药业技术研发有限公司 | Pharmaceutical preparation for preventing nephritis and preparation method thereof |
CN102861088A (en) * | 2012-10-27 | 2013-01-09 | 吴俊华 | Application of Houttuynoid D in medicine for preventing and treating renal insufficiency |
CN103083452A (en) * | 2012-12-11 | 2013-05-08 | 宋协勘 | Traditional Chinese medicine for treating chronic bacterial prostatitis |
CN105311300A (en) * | 2015-11-25 | 2016-02-10 | 范葵 | Pharmaceutical composition, herba houttuyniae suppository and preparation method and application |
CN110384741A (en) * | 2018-04-23 | 2019-10-29 | 金泽明 | Purposes of the cordate houttuynia in the oral preparation of preparation prevention and treatment hyperplasia of prostate |
-
2006
- 2006-02-27 JP JP2006084136A patent/JP2007230983A/en active Pending
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010088367A (en) * | 2008-10-09 | 2010-04-22 | S Net:Kk | Livestock feed |
CN101856418A (en) * | 2010-04-27 | 2010-10-13 | 贵阳春科药业技术研发有限公司 | Pharmaceutical preparation for preventing nephritis and preparation method thereof |
CN102861088A (en) * | 2012-10-27 | 2013-01-09 | 吴俊华 | Application of Houttuynoid D in medicine for preventing and treating renal insufficiency |
CN103083452A (en) * | 2012-12-11 | 2013-05-08 | 宋协勘 | Traditional Chinese medicine for treating chronic bacterial prostatitis |
CN105311300A (en) * | 2015-11-25 | 2016-02-10 | 范葵 | Pharmaceutical composition, herba houttuyniae suppository and preparation method and application |
CN110384741A (en) * | 2018-04-23 | 2019-10-29 | 金泽明 | Purposes of the cordate houttuynia in the oral preparation of preparation prevention and treatment hyperplasia of prostate |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1124134C (en) | Naringin and naringenin as inhibitor of acyl coa-cholesterol-o-acyltransferase, ihibitor of macrophage-lipid complex accumulation on the arterial wall and preventive agent | |
JP3333777B2 (en) | Acyl COA-cholesterol-O-acyl transferase inhibitor, inhibitor of macrophage-lipid complex accumulation on arterial wall, and citrus peel extract as prophylactic or therapeutic agent for liver disease | |
JP2002524480A (en) | Bioflavonoids as hypoglycemic agents | |
JP2007230983A (en) | Prostatic hypertrophy inhibitor | |
JP2019019143A (en) | Inhibitors of vcam-1 expression | |
JP2008214191A (en) | Agent for suppressing accumulation of lipid in liver | |
CN1124133C (en) | Hesperidin and hesperetin as inhibitor of acyl coa-cholesterol-o-acyltransferase, inhibitor of macrophage-lipid complex accumulation on the arterial wall and preventive agent | |
WO2006082743A1 (en) | Therapeutic agent | |
JP5566677B2 (en) | An androgen action inhibitor, prostate enlargement inhibitor, and androgen-dependent hair loss inhibitor containing whole plants other than banana fruit as active ingredients | |
JP5148128B2 (en) | Prostatic hypertrophy inhibitor containing banana peel as an active ingredient | |
KR20180000586A (en) | A pharmaceutical composition comprising extract from germinated gemmule of bean for preventing or treating metabolic disease | |
JP2009114158A (en) | Blood sugar level rising inhibitor | |
JP2007230987A (en) | Anti-obestic agent | |
JP2012131760A (en) | Fatty acid absorption inhibitor | |
JP2012236810A (en) | Prostatomegaly inhibitor containing eckloniopsis radicosa as active constituent | |
JP2009173619A (en) | Prostatic hypertrophy inhibitor containing black seed as active ingredient | |
JP2015078140A (en) | Prevention/treatment agent for alcoholic fatty liver | |
US20090292012A1 (en) | Therapeutic Agent | |
JP2009167153A (en) | Blood glucose level elevation-inhibiting agent | |
JP2005053818A (en) | Trypsin inhibitor | |
JP2010105948A (en) | Fatty liver inhibitor | |
JP2008174532A (en) | Inhibitor of blood glucose level increase | |
JP2007230989A (en) | Endurance enhancing and anti-fatigue agent | |
JP2007230985A (en) | Blood glucose level elevation inhibitor | |
JP2009167154A (en) | Blood glucose level elevation-inhibiting agent |